MAAT INDEX

CLAIM #56400 · Thermo Fisher Scientific Inc (TMO) · 2024Q1 earnings call · Apr 24, 2024 · due Dec 31, 2024

We're assuming between $1.3 billion and $1.5 billion of net capital expenditures and free cash flow in the range of $6.5 billion to $7 billion.

Stephen Williamson · CFO

PENDING
graded after results covering Dec 31, 2024 are reported

How to check this claim

Look at: Free cash flow, fiscal year 2024

It came true if: Full-year 2024 free cash flow between $6.5 billion and $7.0 billion (net capital expenditures between $1.3 billion and $1.5 billion)

Where: Company-reported full-year 2024 results (cash flow statement / Q4 2024 earnings release)

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2024Q1 earnings call.